KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Royalty Pharma (RPRX) Minority Interest (2019 - 2025)

Historic Minority Interest for Royalty Pharma (RPRX) over the last 7 years, with Q4 2025 value amounting to $3.2 billion.

  • Royalty Pharma's Minority Interest fell 464.53% to $3.2 billion in Q4 2025 from the same period last year, while for Dec 2025 it was $3.2 billion, marking a year-over-year decrease of 464.53%. This contributed to the annual value of $3.2 billion for FY2025, which is 464.53% down from last year.
  • According to the latest figures from Q4 2025, Royalty Pharma's Minority Interest is $3.2 billion, which was down 464.53% from $3.2 billion recorded in Q3 2025.
  • In the past 5 years, Royalty Pharma's Minority Interest ranged from a high of $5.0 billion in Q1 2021 and a low of $3.1 billion during Q1 2025
  • Moreover, its 5-year median value for Minority Interest was $3.5 billion (2023), whereas its average is $3.8 billion.
  • As far as peak fluctuations go, Royalty Pharma's Minority Interest plummeted by 1937.76% in 2023, and later crashed by 167.1% in 2024.
  • Royalty Pharma's Minority Interest (Quarter) stood at $4.5 billion in 2021, then decreased by 12.85% to $3.9 billion in 2022, then fell by 8.71% to $3.6 billion in 2023, then decreased by 4.55% to $3.4 billion in 2024, then dropped by 4.65% to $3.2 billion in 2025.
  • Its Minority Interest stands at $3.2 billion for Q4 2025, versus $3.2 billion for Q3 2025 and $3.2 billion for Q2 2025.